News

TB R&D Weekly Update: CSU Identifies Anti-TB Compound against Unique Target

Grzegorzewicz AE, Pham H, Gundi VA, Scherman MS, North EJ, Hess T, Jones V, Gruppo V, Born SE, Korduláková J, Chavadi SS, Morisseau C, Lenaerts AJ, Lee RE, McNeil MR, Jackson M. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol. 2012 Feb 19. doi: 10.1038/nchembio.794. [Epub ahead of print]

This week’s article highlights research out of Colorado State University that identifies a potential anti-TB compound against a unique target– the inner membrane transporter MmpL3 of Mycobacterium tuberculosis–that inhibits an essential cell function of the mycobacteria.

Abstract:

New chemotherapeutics active against multidrug-resistant Mycobacterium tuberculosis are urgently needed. We report on the identification of an adamantyl urea compound that shows potent bactericidal activity against M. tuberculosis and a unique mode of action, namely the abolition of the translocation of mycolic acids from the cytoplasm, where they are synthesized to the periplasmic side of the plasma membrane and are in turn transferred onto cell wall arabinogalactan or used in the formation of virulence-associated, outer membrane, trehalose-containing glycolipids. Whole-genome sequencing of spontaneous-resistant mutants of M. tuberculosis selected in vitro followed by genetic validation experiments revealed that our prototype inhibitor targets the inner membrane transporter MmpL3. Conditional gene expression of mmpL3 in mycobacteria and analysis of inhibitor-treated cells validate MmpL3 as essential for mycobacterial growth and support the involvement of this transporter in the translocation of trehalose monomycolate across the plasma membrane.

Additional Coverage:

Tuberculosis researchers find answer to 30-year-old puzzle

Research by Helena Boshoff’s Lab at the NIH/NIAID also showing MmpL3 as a target of SQ109:

Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker JR, Alland D, Barry CE 3rd, Boshoff HI. SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012 Jan 17. [Epub ahead of print]

Additional TB R&D News:

Otsuka Submits NDA For TB Drug Delamanid in Europe

Old antibiotic could be a new weapon to fight TB

Novel tuberculosis research technology published in JoVE

Gates Foundation Awards $7.7 Million for TB Research

White House releases FY 2013 Budget Request (a look at impact on Global Health Funding)

Infectious Disease Technologies Could Open Investment Opportunities In 2012: Stephen Dunn

WHO’s relationship with the Stop TB Partnership

This week’s article highlights research out of Colorado State University that identifies a potential compound against a unique target– the inner membrane transporter MmpL3 of Mycobacterium tuberculosis–and inhibiting an essential cell function of the mycobacteria.
More News
26 Jun 2018
As the global TB drug development community pushes forward to find new drug candidates and develop novel regimens to combat the TB epidemic, we'd like to highlight some updates in the field, WGND activities, and upcoming events in 2018. An Interactive Civil Society Hearing was held on June 4th in...
21 May 2018
Bloomberg News reported this week on how world leaders can be successful in ending TB by 2030 and the demographics that TB affects most. One article discusses multi-drug and extensive drug resistant patients as well as challenges, funding needs, and the needs for new tools to defeat TB. The other...
17 Apr 2018
A new laborartory resource handbook was published in March 2018 to support TB clinical trials. The authors and summary of the handbook are below. Please click here for a link to the full handbook. Authors Kathleen Eisenach, University of Arkansas for Medical Sciences, USA Anne-Marie Demers, Desmond...